Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer.
Ishii T, Kawazoe A, Sasaki A, Mishima S, Kentaro S, Nakamura Y, Kotani D, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Kuwata T, Ishii G, Shitara K.
Ishii T, et al. Among authors: ishii g.
Ther Adv Med Oncol. 2020 Jul 17;12:1758835920942377. doi: 10.1177/1758835920942377. eCollection 2020.
Ther Adv Med Oncol. 2020.
PMID: 32733607
Free PMC article.